Alzheimer's disease, the most common form of dementia, is a pressing issue for our lifetime. Society needs to be responsive to ensure that people can live with more dignity and access services and resources despite their diagnosis. On 26 September 2023, the European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical [...]
On the occasion of the Brain Awareness Week, the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) launch the RETHINKING Alzheimer's disease White Paper, calling for change in the detection and diagnosis of Alzheimer's disease. About Alzheimer's disease Alzheimer’s disease (AD), the most common form of [...]
Every three seconds someone develops dementia and for most of these individuals this will be as a result of Alzheimer’s disease, the leading cause. Alzheimer's is a relentless neurodegenerative condition which robs people of their memories, their independence, their relationships, and ultimately, their lives. On 24 January 2023, the European Brain Council (EBC), in collaboration [...]
Registration is now open for the launch event of the RETHINKING Alzheimer's disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper [...]
Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health needs. It represents between 60% and 70% of the dementia cases. It is still diagnosed too late when the symptoms become evident as the disease progresses. AD is now portrayed as continuum consisting of 3 stages: [...]
